Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, J Palace (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22:268–282. https://doi.org/10.1016/s1474-4422(22)00431-8

Article  CAS  PubMed  Google Scholar 

Al-Ani A, Chen JJ, Costello F (2023) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol 270:4132–4150. https://doi.org/10.1007/s00415-023-11737-8

Article  PubMed  PubMed Central  Google Scholar 

Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S (2025) MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 24:103693. https://doi.org/10.1016/j.autrev.2024.103693

Article  CAS  PubMed  Google Scholar 

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, Sèze JD, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, B Hemmer (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20:762–772. https://doi.org/10.1016/s1474-4422(21)00218-0

Article  CAS  PubMed  Google Scholar 

Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T (2023) Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol 10:672–685. https://doi.org/10.1002/acn3.51759

Article  PubMed  PubMed Central  Google Scholar 

Guo Y, Tian X, Wang X, Z Xiao (2018) Adverse Effects of Immunoglobulin Therapy. Front Immunol 9:1299. https://doi.org/10.3389/fimmu.2018.01299

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heo YA (2022) Efgartigimod: First Approval. Drugs 82:341–348. https://doi.org/10.1007/s40265-022-01678-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, R Mantegazza (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526–536. https://doi.org/10.1016/s1474-4422(21)00159-9

Article  CAS  PubMed  Google Scholar 

Li Z, Xu Q, Huang J, Zhu Q, Yang X, Zhang M, Zhang S, Huang S, Yu G, Zheng P, Qin X, Feng J (2024) Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case Report. Heliyon 10:e30421. https://doi.org/10.1016/j.heliyon.2024.e30421

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu F, Wang WF, Ma CH, Liang H, Jiang YQ (2024) Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod. J Neurol 271:5911–5915. https://doi.org/10.1007/s00415-024-12556-1

Article  CAS  PubMed  Google Scholar 

Zhu Y, Zhang J, Li H, Wei L, Tian Y, Wang K (2025) Case Report: Efgartigimod as an additional therapy for MOG antibody-associated disease overlapping GFAP-IgG. Front Immunol 16:1624660. https://doi.org/10.3389/fimmu.2025.1624660

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du J, Cao S, Cao L, Tian Y, Qi X (2025) A Case Report of Efgartigimod in the Treatment of Recurrent Severe Anti-NMDAR Encephalitis Complicated with MOGAD (P10-8.016). Neurology 104:4509. https://doi.org/10.1212/WNL.0000000000211721

Article  Google Scholar 

Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, EP Flanagan (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 13:885218. https://doi.org/10.3389/fneur.2022.885218

Article  PubMed  PubMed Central  Google Scholar 

Huang SQ, Yuan ZH, Hong Y, Jiang T, Zhao HD, Shi JQ (2024) Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report. Neurol Sci 45:5511–5515. https://doi.org/10.1007/s10072-024-07678-3

Article  PubMed  Google Scholar 

Shimizu F, M Nakamori (2024) Blood-Brain Barrier Disruption in Neuroimmunological Disease. Int J Mol Sci 25. https://doi.org/10.3390/ijms251910625

Tanaka K, Kezuka T, Ishikawa H, Tanaka M, Sakimura K, Abe M, Kawamura M (2023) Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review. Int J Mol Sci 24. https://doi.org/10.3390/ijms241713368

Kosior N, Perrier RL, Casserly C, Morrow SA, Racosta JM (2024) New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD. Mult Scler Relat Disord 92:105941. https://doi.org/10.1016/j.msard.2024.105941

Article  CAS  PubMed  Google Scholar 

Chen JJ, Flanagan EP, Pittock SJ, Stern NC, Tisavipat N, Bhatti MT, Chodnicki KD, Tajfirouz DA, Jamali S, Kunchok A, Eggenberger ER, Nome MAD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Moss HE, Navarro SEV, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Danesh-Meyer H, Ivanov S, Huda S, Forcadela M, Hodge D, Poullin P, Rode J, Papeix C, Saheb S, Vignal C, Hacohen Y, Pique J, Maillart E, Deschamps R, Audoin B, R Marignier (2023) Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. Am J Ophthalmol 252:213–224 M Boudot de la Motte. https://doi.org/10.1016/j.ajo.2023.02.013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Kong L, Zhao Z, Shi Z, Chen H, Lang Y, Lin X, Du Q, Zhou H (2022) Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis. Front Immunol 13:953993. https://doi.org/10.3389/fimmu.2022.953993

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sneed SL, Reese BB, Laureano AF, Ratnapriya S, Fraschilla I, Jeffrey KL, Coffey GP, Conley PB, RM Anthony (2024) An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin. J Clin Invest 134. https://doi.org/10.1172/jci172980